Company

Hengrui Wins NMPA Trial Clearance for First-in-Class SHR-2005 Combination in Bladder Cancer
CancerClinical trial approval / initiation

Hengrui Wins NMPA Trial Clearance for First-in-Class SHR-2005 Combination in Bladder Cancer

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that China's National Medical Products Administration (NMPA) has approved the initiation of a clinical trial of SHR‑2005 injection, in combination…

AstraZeneca's Imfinzi Combo Cuts Death Risk 42% in Phase III VOLGA Trial – Landmark Perioperative Win in Muscle-Invasive Bladder Cancer

AstraZeneca’s Imfinzi Combo Cuts Death Risk 42% in Phase III VOLGA Trial – Landmark Perioperative Win in Muscle-Invasive Bladder Cancer

InnoCare Pharma Q3 Revenue Surges 150.6% as Orelabrutinib Expansion Drives Turnaround to Profitability

InnoCare Pharma Q3 Revenue Surges 150.6% as Orelabrutinib Expansion Drives Turnaround to Profitability

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC
ADC / XDCClinical trial approval / initiation

Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC

Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler
BiotechChance Pharmaceuticals

Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler

Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform
Cell-therapyNYSE: TAK

Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform

Mirxes Secures China’s First Blood‑Test Approval for Gastric‑Cancer Screening
CancerHKG: 2629

Mirxes Secures China’s First Blood‑Test Approval for Gastric‑Cancer Screening

Show More